This study investigated the relapse and outcome patterns of patients with central nervous system mixed malignant germ cell tumors treated with chemotherapy-only ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• June 2015

To investigate whether maternal coffee and/or tea consumption during the last 6 months of pregnancy was associated with risk of childhood ALL. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2011
• February 2011

In T-cell acute lymphoblastic leukemia (T-ALL) cytogenetic alterations juxtapose the LIM-domain-only-2 gene (LMO2) with T-cell receptor loci. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2011
• June 2011

The objective of this study was to investigate whether maternal coffee and/or tea consumption during the last 6 months of pregnancy was associated with risk... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2011
• January 2011

Despite initial improvements in survival of infants with ALL since establishment of the first pediatric cooperative group ALL trials, the poor outcome has... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2014
• April 2014

Here we report that CHAF1B is required for normal hematopoiesis while its overexpression promotes leukemia ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2018
• November 2018

Immunotherapies have revolutionized cancer treatment. In particular, immune checkpoint therapy (ICT) leads to durable responses in some patients with some cancers. However, the majority of treated patients do not respond. Understanding immune mechanisms that underlie responsiveness to ICT will help identify predictive biomarkers of response and develop treatments to convert non-responding patients to responding ones. ICT primarily acts at the level of adaptive immunity. The specificity of adaptive immune cells, such as T and B cells, is determined by antigen-specific receptors. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2020
• October 2020

There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during and after first-line chemotherapy with cisplatin and pemetrexed in patients with advanced malignant pleural mesothelioma. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2020
• September 2020

This review explores computational strategies to yield biological insight into the processes involved in the immunotherapeutic response ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2019
• June 2019

This study thus identified a novel small molecule that rapidly kills MLL-rearranged leukemia cells by targeting a metabolic vulnerability ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2019
• May 2019